We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunofluorescence Assay Market Worth USD 2 Billion by 2023

By LabMedica International staff writers
Posted on 01 Mar 2018
Print article
The global immunofluorescence assay market estimated to be worth USD 1.51 billion in 2018 and is projected to grow at a CAGR of 5.8% to reach USD 2.01 billion by 2023, driven by the growing prevalence of chronic diseases, increasing R&D spending, and rise in healthcare spending.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a global market research company.

On the basis of product, the reagents segment held the largest share of the global immunofluorescence assay market due to growing applications of biosciences and biotechnology in the pharmaceutical and healthcare fields, rising prevalence of a number of diseases, increasing R&D activities, and government initiatives to strengthen national research capabilities. On the basis of disease, the cancer segment held the largest share of the immunofluorescence assay market, driven by the increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer.

On the basis of type, the indirect immunofluorescence assay segment held the largest market share, driven by the increasing adoption of the indirect immunofluorescence technique owing to its advantages such as sensitivity, flexibility, better signal amplification, and lower cost than the direct immunofluorescence technique. On the basis of end-user, the pharmaceutical and biotechnology companies segment held the largest share of the immunofluorescence assay market, due to the increasing use of immunofluorescence assay in the study of various diseases and drug discovery & development processes in pharmaceutical and biotechnology companies.

In 2017, North America held the largest share of the global immunofluorescence assay market, followed by Europe and Asia Pacific. The large share of the North American immunofluorescence assay market is mainly due to the rising incidence of chronic & infectious diseases, increasing R&D spending, growing research activities, favorable government funding opportunities, and the presence of key players in the region.

Related Links:
MarketsandMarkets

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Automated Blood Typing System
IH-500 NEXT
New
Toxoplasma Gondii Test
Toxo IgG ELISA Kit
New
FLU/RSV Test
Humasis FLU/RSV Combo

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.